Marksans Pharma vs Sequent Scientific: Share Price, Comparison and Key Differences
- August 12, 2026
- Posted by: Neeraj Pandey
- Category: News
Marksans Pharma MCap Rs 12,408 Cr, PE 29.54x, ROE 13.82%, D/E 0.11. Sequent Scientific MCap Rs 12,106 Cr, PE 53.91x, ROE 7.07%, D/E 0.17. Near-equal size!
Marksans Pharma vs Sequent Scientific is a comparison pharma investors look up when evaluating two listed Indian companies with different pharma strategies at nearly equal market capitalization. Marksans Pharma, a Mumbai-based company, is a generic pharmaceutical company selling branded generic medicines in UK, USA, Australia and other regulated markets – known for OTC (over-the-counter) products including paracetamol tablets, ibuprofen and branded OTC under its own brands. Sequent Scientific, a Mumbai-based company (Carlyle Group-backed), is a global animal health API and formulations company manufacturing veterinary APIs (active pharmaceutical ingredients) and veterinary finished dose products for regulated markets. Both Marksans vs Sequent Scientific are in pharma but serve human generics versus animal health API.
This Marksans Pharma vs Sequent Scientific article covers reach and market position, key products, latest declared results and stock valuation. All data is sourced from Groww and public company filings.
Reach and Market Position
In this Marksans Pharma vs Sequent Scientific comparison, Marksans sells OTC generic medicines in UK, Australia, Germany, USA and other countries under its own brands (Tick Tock, Coopers, Prescient) and through pharmacy chains. Market capitalisation is Rs 12,408 Cr.
Click Here – Get Free Investment Predictions
Sequent Scientific manufactures veterinary APIs and veterinary finished dose products for regulated markets in EU, USA, Brazil and other countries. Market capitalisation is Rs 12,106 Cr.
Key Products and Business Mix
For the Marksans Pharma vs Sequent Scientific product breakdown, Marksans Pharma: Marksans earns from OTC generic medicines (paracetamol, ibuprofen tablets, antacids) sold through pharmacy retail in Western markets. EPS is Rs 9.27. PE is 29.54x, ROE 13.82 percent, D/E 0.11.
Sequent Scientific: Sequent Scientific earns from veterinary API and animal health API for global animal health companies. EPS is Rs 5.14. PE is 53.91x, ROE 7.07 percent, D/E 0.17.
Latest Results and Financial Data
On the Marksans Pharma vs Sequent Scientific results front: Marksans Pharma has a market cap of Rs 12,408 Cr and PE of 29.54x. ROE is 13.82 percent. Marksans and Sequent are near-equal in size (Rs 12,408 Cr vs Rs 12,106 Cr).
Sequent Scientific has a market cap of Rs 12,106 Cr and PE of 53.91x. ROE is 7.07 percent. Sequent is nearly identical in size to Marksans but twice as expensive on PE with a lower ROE.
Compare Marksans Pharma and Sequent Scientific Fundamentals on the Univest Screener
Stock Performance and Valuation
Investors tracking the Marksans Pharma vs Sequent Scientific comparison should verify current prices on NSE or BSE before trading. The Marksans Pharma vs Sequent Scientific stock data below reflects the latest available figures from Groww and public company filings.
Marksans vs Sequent at current valuations: Marksans trades at Rs 12,408 Cr, PE 29.54x, ROE 13.82 percent. Sequent trades at Rs 12,106 Cr, PE 53.91x, ROE 7.07 percent. Near-equal market caps. Marksans is much cheaper on PE with a higher ROE. Sequent has a premium PE for its animal health specialty niche.
Marksans Pharma vs Sequent Scientific: Quick Comparison Table
The comparison table below summarises the key metrics side by side.
| Parameter | Marksans Pharma | Sequent Scientific |
|---|---|---|
| Sector | Generic OTC pharma: paracetamol, ibuprofen (UK, Australia, USA brands) | Animal health API + veterinary formulations for regulated markets |
| Market Cap | Rs 12,408 Cr | Rs 12,106 Cr (near-equal!) |
| P/E Ratio | 29.54x | 53.91x |
| ROE | 13.82% | 7.07% |
| Market | Human generic OTC (Western markets – own brands) | Veterinary API global regulated markets |
| Debt to Equity | 0.11 | 0.17 |
| Key Products | Paracetamol, ibuprofen, antacids (OTC brands) | Veterinary APIs for livestock and companion animals |
Conclusion
The Marksans Pharma vs Sequent Scientific comparison above covers reach, products, results and valuation. Marksans Pharma vs Sequent Scientific covers human generic OTC medicines in Western markets versus animal health API globally. Marksans is cheaper on PE with solid ROE. Sequent has a premium PE for its unique animal health API niche. Marksans vs Sequent investors should track OTC pharma market conditions and animal health API demand trends. Consult a SEBI-registered advisor for personalised guidance.
Download the Univest iOS App or Univest Android App to track Marksans Pharma and Sequent Scientific live price and get daily stock recommendations.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What does Marksans Pharma sell?
Ans. Marksans Pharma sells over-the-counter generic medicines under its own brands in the UK (Tick Tock, Coopers), Australia (Prescient) and other markets. Products include paracetamol tablets, ibuprofen, antacids, and cold/flu preparations.
What does Sequent Scientific do?
Ans. Sequent Scientific manufactures active pharmaceutical ingredients (APIs) specifically for animal health – antibiotics, antiparasitics, hormones and other veterinary molecules – for global animal health companies.
What is a veterinary API?
Ans. A veterinary API is an active pharmaceutical ingredient manufactured specifically for use in medicines treating animals (livestock, pets, aquaculture). Sequent Scientific specializes in complex veterinary APIs requiring specialized regulatory compliance.
Are Marksans and Sequent in Nifty 50?
Ans. Neither is in Nifty 50. Both are tracked in smaller indices.
Which is larger?
Ans. Marksans Pharma at Rs 12,408 Cr and Sequent Scientific at Rs 12,106 Cr are essentially equal in size – among the closest-matched pairs in this batch.
Who owns Sequent Scientific?
Ans. Sequent Scientific is backed by Carlyle Group (USA private equity) which holds a significant stake.
Does Marksans have a moat?
Ans. Marksans’ competitive advantage is its own-brand OTC platform in UK and Australia – branded shelf space in pharmacy chains provides recurring demand for its generic OTC products.
